STOCK TITAN

Prosight group files 13G/A showing 5.8% of ADCT

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ADC Therapeutics (ADCT): Schedule 13G/A—Prosight Management and affiliated reporting persons disclosed beneficial ownership of 7,195,374 common shares, representing 5.8% of the class, with shared voting and dispositive power over those shares and no sole power. The event date is 09/30/2025. The percentage is based on 123,877,111 shares outstanding as of October 31, 2025.

Within the group, Prosight Fund holds 350,415 shares (0.3%) and Prosight Plus Fund holds 1,586,895 shares (1.3%). The filing certifies the securities were not acquired for the purpose of changing or influencing control of the issuer.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 common shares ("Common Shares") of ADC Therapeutics SA (the "Issuer") outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the "Commission") on November 10, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.


SCHEDULE 13G



Prosight Management, LP
Signature:Prosight Partners, LLC
Name/Title:General Partner
Date:11/13/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner
Date:11/13/2025
Prosight Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:11/13/2025
Signature:Prosight Partners, LLC
Name/Title:Sole Manager of the General Partner
Date:11/13/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:11/13/2025
Prosight Plus Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:11/13/2025
Signature:Prosight Partners, LLC
Name/Title:General Partner of the General Partner
Date:11/13/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:11/13/2025
Prosight Partners, LLC
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager
Date:11/13/2025
W. Lawrence Hawkins
Signature:/s/ W. Lawrence Hawkins
Name/Title:W. Lawrence Hawkins
Date:11/13/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on April 17, 2023, by the Reporting Persons with the SEC).

FAQ

What ownership did Prosight report in ADCT?

7,195,374 common shares, representing 5.8% of the class, with shared voting and dispositive power.

What is the reference share count for ADCT used in this filing?

The percentage is based on 123,877,111 shares outstanding as of October 31, 2025.

Which Prosight entities are included and what do they hold?

Prosight Fund holds 350,415 shares (0.3%); Prosight Plus Fund holds 1,586,895 shares (1.3%).

Does the filing indicate any intent to influence control of ADCT?

It certifies the shares were not acquired for the purpose of changing or influencing control.

Who are the reporting persons on this 13G/A?

Prosight Management, LP; Prosight Fund, LP; Prosight Plus Fund, LP; Prosight Partners, LLC; and W. Lawrence Hawkins.

What type of voting power is reported?

Shared voting and dispositive power over 7,195,374 shares; no sole power reported.
Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Latest SEC Filings

ADCT Stock Data

483.12M
100.92M
19.02%
64.57%
3.68%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
EPALINGES